StockNews.AI
VXRT
StockNews.AI
11 days

Vaxart to Present at World Vaccine Congress Washington 2025 on April 23

1. Vaxart will present at World Vaccine Congress on April 23, 2025. 2. Two key topics include oral vaccination strategies and immune profiling for norovirus. 3. Vaxart's oral vaccines target diseases like coronavirus, norovirus, and HPV. 4. The company's innovative delivery platform offers pills stored without refrigeration. 5. Vaxart continues to participate in industry events enhancing visibility and credibility.

4 mins saved
Full Article

FAQ

Why Bullish?

The upcoming presentations showcase Vaxart's innovative vaccine technologies, positively influencing investor perception and interest. Historically, successful event presentations often lead to stock price increases for biotech firms, as seen with companies like Moderna post-conferences.

How important is it?

The article discusses Vaxart's participation in a significant vaccine conference, which can impact its investor relations and stock market performance. Engaging with key industry figures enhances the company's credibility and could lead to collaborations.

Why Short Term?

Increased visibility from the presentations may lead to immediate market interest and potential partnerships, influencing stock performance shortly after the event.

Related Companies

MRNANVAXBNTX
April 16, 2025 08:00 ET  | Source: Vaxart, Inc. SOUTH SAN FRANCISCO, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James F. Cummings, Chief Medical Officer, will present at the World Vaccine Congress Washington 2025 in Washington, D.C. on Wednesday, April 23, 2025. The Company has appeared repeatedly at the annual event in Washington, D.C. Presentation Information: Title: Moving the needle: Blocking transmission and boosting existing vaccines by oral tablet vaccinationSpeaker: Dr. James F. CummingsDate: Wednesday, April 23, 2025 Time: 1:10 p.m. ETRoom: 207A Title: Immune profiling on an oral norovirus vaccine candidate; correlates of protection for disease and infectionSpeaker: Dr. Sean TuckerDate: Wednesday, April 23, 2024 Time: 3:10 p.m. ETRoom: 207A About Vaxart Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists. ContactVaxart Media and Investor Relations:   Matt Steinberg      FINN PartnersIR@vaxart.com(646) 871-8481 This press release was published by a CLEAR® Verified individual.

Related News